GOSSAMER BIO, INC.
GOSS US38341P1021
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Milligan Sandra |
1.92 USD |
26,050 Bought |
50,016 USD |
19/08/2025 | 19/08/2025 |
| Aranda Richard CMO |
0.66 USD |
1,908 Sold |
1,260 USD |
24/06/2024 | 24/06/2024 |
| Hasnain Faheem CEO |
0.67 USD |
372,000 Bought |
250,282 USD |
21/06/2024 | 21/06/2024 |
| Giraudo Bryan COO |
0.59 USD |
100,000 Bought |
59,110 USD |
18/06/2024 | 18/06/2024 |
| Smith Robert Paul Jr CCO |
0.60 USD |
25,000 Bought |
15,050 USD |
17/06/2024 | 17/06/2024 |
| Giraudo Bryan COO |
1.16 USD |
6,430 Sold |
7,431 USD |
27/03/2024 | 27/03/2024 |
| Hasnain Faheem CEO |
1.16 USD |
23,172 Sold |
26,773 USD |
27/03/2024 | 27/03/2024 |
| Christian Waage EX VP |
1.16 USD |
6,430 Sold |
7,430 USD |
27/03/2024 | 27/03/2024 |
| Peterson Caryn EX VP |
1.33 USD |
4,018 Sold |
5,343 USD |
18/03/2024 | 18/03/2024 |
| Aranda Richard CMO |
1.33 USD |
4,018 Sold |
5,342 USD |
18/03/2024 | 18/03/2024 |